The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.
MDC Connects 2021: A Guide to Complex Medicines is a series of webinars exploring the opportunities and challenges presented by this new class of medicines, and takes you through the steps to take an idea from concept to the clinic.
In this first webinar, we will introduce the new and diverse field of complex medicines, the commercial opportunity presented and the current state of research in the UK community.
What is the commercial opportunity? – David Cook (Blueberry Therapeutics)
Shaping the UK into an international leader for complex medicines – Prof. Peter Simpson (MDC)
Complex medicines: The target landscape – Dr Duygu Yilmaz (MDC)
In this session, we will look at assays, technologies and capabilities which can be employed to characterise the lead molecule.
Developing the assay cascade for complex medicines – Tilly Bingham (Concept Life Sciences)
Cellular internalisation and trafficking of complex medicines – Dr Jamie Szczerkowski (MDC)
CryoEM in characterisation and quality control of complex medicines – Rebecca Thompson (Astbury Biostructure Laboratory)
What can be learnt from traditional lead optimisation campaigns? In this webinar, we consider how to turn a lead in to a molecule with potential to be a medicine.
The early assessment of prototype nanomedicine nano-bio interactions – Zahra Rattray (University of Strathclyde)
The interaction of colloidal gene delivery vehicles with model biomembranes – Jayne Lawrence (The University of Manchester)
The challenges of determining drug levels and PK profiles for complex drug modalities – Robert Wheller (LGC)
At this midpoint in the webinar series, we will hear from the pioneers developing complex medicines and the challenges presented and overcome.
Lipid nanoparticles – so much more than a little fat blob – Yvonne Perrie (University of Strathclyde)
“Bursting with promise” – precision drug delivery with Therapeutic Microbubbles – Louise Coletta (University of Leeds)
Under the radar: alternative delivery of mRNA vaccines – Helen McCarthy (pHion Therapeutics)
Here experts describe how to establish preclinical safety and efficacy data for complex medicines and how this compares with conventional drug discovery.
Determining efficacy in vivo – Jenny Worthington (Axis Bio)
Physicochemical characterisation: new and novel approaches to understand the pharmacokinetics of complex drugs – Juliana Maynard (MDC)
Do complex medicines raise different challenges from a safety perspective? – Richard Knight (ApconiX)
